16/10/2014 08:42:21

EXINI to arrange Bone Scan Index (BSI) symposium at important annual European congress

Lund, Sweden, 2014-10-16 09:42 CEST (GLOBE NEWSWIRE) --

EXINI and FUJIFILM RI Pharma will arrange a Bone Scan Index (BSI) symposium on

October 20th at this year’s EANM-congress (European Association of Nuclear

Medicine) held in Gothenburg, October 18-22.

The symposium called ”Bone Scan Index (BSI) A Nuclear Medicine Biomarker in

Metastatic Prostate Cancer”, commence at 13.00 p.m. For more information >>

Program

”The symposium provide a unique opportunity for invited physicians within

nuclear medicine, to learn more about the imaging biomarker BSI and its

clinical applications. Arranging it together with our partner FUJIFILM RI

Pharma adds extensive clinical experience and insights gained from the success

of our product EXINI boneBSI (Bonenavi) on the Japanese market ”, comments

Magnus Aurell, CEO, EXINI Diagnostics AB.

Throughout the congress, several academic studies based upon use of the

software EXINI boneBSI and its BSI-calculating capacity, will be presented:

OP365: Prognostic value of bone scan index for treatment response and survival

in patients with high-risk prostate cancer. M. Reza, A. Bjartell, M. Ohlsson,

R. Kaboteh, P. Wollmer, L. Edenbrandt, E. Trägård

P491: Analytical validation of automated bone scan index as a candidate imaging

biomarker for advanced prostate cancer. A. Anand, L. Edenbrandt, A. Bjartell,

D. Minarik

P502: Reproducibility of automated bone scan index in patients with advanced

prostate cancer. A. Anand, L. Båth, R. Kaboteh, A. Bjartell, L. Edenbrandt

P786: Routine usefulness analysis of computer assisted diagnosis (CAD) software

for bone scan index L. Ferrer, M. Colombie, D. Rusu, D. Goulon, B. Jamet, N.

Varmenot, F. Kraeber-Bodere, C. Rousseau

More on Bone Scan Index (BSI):

BSI is an imaging biomarker providing fast, accurate and quantifiable

information to be used for diagnosis and stratification and the monitoring of

treatment response. It also provides increased accuracy in prognoses involving

patients suffering from skeletal metastases originating from prostate- or

breast cancer.

What is more, BSI has demonstrated its importance in the process of developing

new drugs, thus proving itself just as important for clinical use as for the

pharmaceutical industry. EXINI boneBSI is the only software capable of

extracting BSI-values for both these purposes.

www.bonescanindex.org

www.exini.com/software-bone-bsi/

For more information, please contact:

Magnus Aurell, CEO

Phone: +46 46 286 54 25

E-mail: magnus.aurell@exini.com

About EXINI Diagnostics AB (publ)

EXINI Diagnostics AB (publ) offers advanced solutions for medical decision

support to hospitals worldwide. The system is based on advanced image analysis

by artificial intelligence and can make its own interpretation of medical

images and provide diagnostic suggestions. In this way the system is used as a

decision support for the diagnosing doctor. EXINI is working with products for

the diagnosis of some of the most frequent endemic diseases such as cancer,

coronary heart disease, dementia and Parkinson's disease. The company was

founded in 1999 by Professor Lars Edenbrandt. EXINI is listed on the stock

market NASDAQ OMX First North and has about 600 shareholders. Principal owner

is Bo Håkansson. Consensus acts as Certified Adviser.

________________________________________________________________________

EXINI Diagnostics AB, Ideon Science Park, Scheelevägen 27, SE-223 70

Lund, Sweden

Phone: +46 46 286 54 20, Fax: +46 46 286 54 29, info@exini.com,

www.exini.com

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
14 Aug
PNDORA
  Jeg har løbende adgang til Carnegies analyser af Pandora og har senest i dag modtaget seks slides,..
55
18 Aug
VWS
Normal 0 false false false DA X-NONE X-NONE ..
30
16 Aug
BAVA
Kære Bavarian aktionærer jeg har forsøgt at samle lidt informationer sammen dels taget fra ”sodazare..
23
17 Aug
 
Hvis du ikke kan tåle -1,5% uden at skulle skrive et indlæg om at gå kontant, er aktiemarkedet for h..
21
13 Aug
VWS
Godaften allesammen Jeg mener at analytikkernes estimat for Vestas ordre indtag fir indeværende år..
20
15 Aug
VWS
Hej Per.   1) Når et selskab køber aktier bliver de en del af virksomhedens ejendom - de kan derfor ..
15
14 Aug
ONXEO
Jeg vil gerne give et brush up. Mit udgangspunkt er, at jeg har aktier i selskabet og derfor har nog..
15
15 Aug
VWS
Stop nu dig selv menneske. Du har tudet og vrælet op om, hvor elendigt kursen har ageret siden oktob..
14
16 Aug
NOVO-B
Jeg synes lige at I skal læse disse kloge ord:   For those of you who watch what you eat. Here’s the..
13
14 Aug
VELO
  Gør mit bedste for at forholde mig til facts, også omkring væksten, selvom jeg ikke er fejlfri, er..
13

Majedie Asset Management Ltd : Form 8.3 - TESCO PLC

18/08/2017 15:36:47
FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code")   1.         KEY INFORMATION   (a) Full name of discloser: ..

Alliance Trust PLC : Net Asset Value(s)

18/08/2017 12:56:57
ALLIANCE TRUST PLC                                    At the close of business on Thursday 17 August 2017: The Company's NAV per ordinary share, valued on a bid price basis with Debt at Par, was -       excluding income, 761.7p -       including income, 771.7p  The Company's NAV per ordinary share, valued on a bid price basis with Debt at Fair Value, was -       excluding inc..

Form 8.5 (EPT/RI) - Tesco plc

18/08/2017 08:17:38
FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY 1.         KEY INFORMATION (a) Name of exempt principal trader:   Investec Bank plc   (b) Name of offeror/offeree in relation to whose relevant se..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
RAYONIER SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Rayonier Advanced Materials, Inc. - (RYAM)
2
ALLERGAN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Allergan, Inc. - (AGN)
3
BLUE APRON SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Blue Apron Holdings, Inc. - (APRN)
4
IMPORTANT EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Tableau Software, Inc. and Reminds Investors with Losses to Contact the Firm
5
IMPORTANT EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Forterra, Inc. and Encourages Investors with Losses to Contact the Firm

Buy and sell signals

  • Trend
  • Moneymachine

Latest news


Copyright Euroinvestor A/S 2017   Disclaimer and Terms of Use
Quote information is delivered by Interactive Data.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
19 August 2017 19:44:42
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20170808.1 - EUROWEB5 - 2017-08-19 20:44:42 - 2017-08-19 19:44:42 - 1000 - Website: OKAY